Compare Ginkgo Bioworks Holdings Inc (DNA) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Meta Platforms Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.93 (market cap $763.64M), while Meta Platforms Inc trades at $720.3 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 2409.5× Ginkgo Bioworks Holdings Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Meta Platforms Inc for 127 Days on average.
| DNA | META | |
|---|---|---|
Market Cap | $763.64M | $1.84T |
Volume | 3,204,177 | 15,887,049 |
Sector | Health | Media |
52-Week High | $15.83 | $777.59 |
52-Week Low | $5.48 | $525.72 |
Typical Hold Time | 7 Days | 127 Days |
Enterprise Value | $865.59M | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
META trades at $723.54, up 0.31% on the day, with a bullish technical signal from moving averages and support at $714. The company reported strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a $21B deal with CoreWeave, driving positive sentiment.
The outlook is positive with an 80% analyst buy rating and a consensus price target of $781, but risks include ongoing youth addiction lawsuits and high capital expenditures. Revenue is projected to grow to $228.2B in 2026, supporting long-term growth despite near-term legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
